CAS 508233-74-7|Vortioxetine
| Common Name | Vortioxetine | ||
|---|---|---|---|
| CAS Number | 508233-74-7 | Molecular Weight | 298.446 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 424.8±45.0 °C at 760 mmHg |
| Molecular Formula | C18H22N2S | Melting Point | / |
| MSDS | / | Flash Point | 210.7±28.7 °C |
Names
| Name | vortioxetine |
|---|---|
| Synonym | More Synonyms |
Vortioxetine BiologicalActivity
| Description | Vortioxetine is a inhibitor of 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT, with Ki values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>Serotonin TransporterResearch Areas >>Neurological Disease |
| Target | 5-HT1A Receptor:15 nM (Ki) 5-HT1B Receptor:33 nM (Ki) 5-HT3A Receptor:3.7 nM (Ki) Human 5-HT7 Receptor:19 nM (Ki) SERT:1.6 nM (Ki) |
| In Vitro | Vortioxetine (Compound 5m) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with Ki values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. Vortioxetine displays antagonistic properties at 5-HT3A and 5-HT7 receptors, partial agonist properties at 5-HT1B receptors, agonistic properties at 5-HT1A receptors, and potent inhibition of SERT[1]. Vortioxetine is a partial h5-HT 1B receptor agonist with EC50 of 460 nM and intrinsic activity of 22% using a whole-cell cAMP-based assay. Vortioxetine binds to the r5-HT 7 receptor with a Ki value of 200 nM and is a functional antagonist at the r5-HT7 receptor with an IC50 of 2 μM in an in vitro whole-cell cAMP assay[5]. |
| In Vivo | Vortioxetine (Lu AA21004) occupies the r5-HT1B receptor and rSERT (ED50= 3.2 and 0.4 mg/kg, respectively) after subcutaneous administration and is a 5-HT3 receptor antagonist[6]. Vortioxetine significantly increases cell proliferation and cell survival and stimulates maturation of immature granule cells in the sub granular zone of the dentate gyrus of the hippocampus after 21 days of treatment[3]. Vortioxetine does not cause cognitive or psychomotor impairment[4]. |
| References | [1]. Bang-Andersen B, Ruhland T, J?rgensen M, Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. [2]. Guilloux JP, Mendez-David I, Pehrson A, Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159. [3]. Theunissen EL, Street D, H?jer AM, A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93(6):493-501. [4]. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66. [5]. M?rk A, Pehrson A, Brennum LT, Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 424.8±45.0 °C at 760 mmHg |
| Molecular Formula | C18H22N2S |
| Molecular Weight | 298.446 |
| Flash Point | 210.7±28.7 °C |
| Exact Mass | 298.150360 |
| PSA | 40.57000 |
| LogP | 4.26 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.643 |
| InChIKey | YQNWZWMKLDQSAC-UHFFFAOYSA-N |
| SMILES | Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1 |
| Storage condition | 2-8°C |
Safety Information
| Hazard Codes | Xi |
|---|---|
| HS Code | 2933599090 |
Customs
| HS Code | 2933599090 |
|---|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Synonyms
| 1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine |
| Piperazine, 1-[2-[(2,4-dimethylphenyl)thio]phenyl]- |
| Lu AA 21004 |
| Vortioxetine |
| 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine |
| 1-[2-(2,4-dimethylphenyl)sulfanylphenyl]piperazine |
| Lu AA21004 |
